Business Context and Reporting Period
This Form 8-K Current Report was filed by Madrigal Pharmaceuticals, Inc. on August 11, 2016. The filing reports the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and director compensation.
Material Changes
The primary material change reported is the appointment of Richard S. Levy, M.D., to the Board of Directors as a Class III member, effective immediately. Dr. Levy was also appointed to the Compensation Committee and the Nominating and Governance Committee.
Management Commentary and Compensation
The Board determined Dr. Levy's appointment based on his extensive experience in the pharmaceutical and biotechnology industries, including prior executive roles at Incyte Corporation, Celgene Corporation, and DuPont Pharmaceuticals. There are no reportable transactions between the Company and Dr. Levy under Item 404(a) of Regulation S-K.
Compensation Arrangements:
- Annual Cash Retainer: $40,000.
- Committee Retainers: $7,500 per year for each of the Compensation and Nominating and Governance Committees.
- Initial Stock Option Grant: 20,000 shares (50% vesting on the first anniversary; remainder vesting quarterly).
- Annual Stock Option Grant: 10,000 shares (vesting in full on the first anniversary).
- Expenses: Reimbursement for travel and out-of-pocket expenses.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the stock options granted to Dr. Levy.
- Confirm the total number of directors on the Board following this appointment.
- Review the attached Press Release (Exhibit 99.1) for additional context on the appointment.
- Check subsequent filings for any changes to the Board composition or committee assignments.